Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
| ▸ | EED | O75530 | 1/20 | 0.41 |
| ▸ | NMT1 | P30419 | 6/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1022439 | 0.84 | ADRB1 (0.51) | HTR6HTR1BNMT1ADRB1HTR2C | |
| SCHEMBL2011864 | 0.84 | HTR1B (0.42) | HTR6HTR1BEEDNMT1HRH3 | |
| SCHEMBL2008345 | 0.81 | ADRB1 (0.47) | HTR6HTR1BNMT1ADRB1SLC6A2 | |
| SCHEMBL2005739 | 0.80 | HTR6 (0.44) | HTR6HTR1BNMT1ADRB1ALPL | |
| SCHEMBL2014369 | 0.78 | HTR6 (0.44) | HTR6HTR1BEEDNMT1ADRB1 | |
| SCHEMBL2014367 | 0.78 | HTR6 (0.44) | HTR6HTR1BNMT1ADRB1SLC6A2 | |
| SCHEMBL4684463 | 0.76 | NMT1 (0.41) | HTR6NMT1ADRB1SLC6A2SLC6A4 | |
| SCHEMBL12643195 | 0.74 | MAPT (0.42) | HTR6HRH3ALPL | |
| SCHEMBL21098564 | 0.73 | ADRB1 (0.59) | HTR6EEDADRB1HTR2C | |
| SCHEMBL4272059 | 0.73 | ADRB1 (0.59) | HTR6EEDADRB1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960556-B2 | Thiadiazole derivatives for the treatment of neuro-degenerative diseases | NV REMYND (BE) | 2011-06-14 | — | — | US | disclosed |
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-06-10 | — | — | US | disclosed |
| EP-2094677-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV Remynd (BE) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008061781-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | SNCA, PARK7, PRNP | HTR6 2082/4885HTR1B 1020/4885EED 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.